← Back to Search

Cholinergic Blocker for Cognitive Impairment

Q: Is this experiment actively enrolling participants?

Clinicaltrials.gov documents reveal that this research experiment, which was first advertised on April 21st 2022, is currently enrolling participants. The details of the trial were most recently updated on June 6th 2022.

Q: How many people is the research team recruiting for this experiment?

Affirmative, the information on clinicaltrials.gov reveals that this medical investigation is in search of volunteers. This study was initially listed on April 21st 2022 and has recently been modified on June 6th 2022. Twenty individuals are required to be enrolled at single site for successful completion of this trial.

Q: Have any prior research projects explored the effects of Mecamylamine Challenge?

Currently, two active medical studies are underway to research Mecamylamine Challenge. These trials are at the Phase 0 level and have locations in both Nashville and <a href="https://www.withpower.com/clinical-trials/tennessee">Tennessee</a>.

Phase < 1

Recruiting

Research Sponsored by Vanderbilt University Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

age ≥ 55

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up after administration of second drug challenge, approximately 72 hours

Awards & highlights

Study Summary

This trial will use a medicine that blocks a chemical called "acetylcholine" to study how it affects attention in people with Sickle Cell Disease. They think that people with SCD have to work harder to pay attention, and disrupting this process with the medicine will make it harder to pay attention.

Who is the study for?

This trial is for non-smoking adults aged 55 or older who have mild cognitive issues but are generally in good health. They should score above 25 on the MoCA test, indicating only slight memory concerns, and have a GDS rating below 3, showing minimal daily life impact.Check my eligibility

What is being tested?

The study tests how an anticholinergic drug called Mecamylamine affects attention in aging individuals with slight cognitive decline. Participants will be compared to those taking a placebo while their brain activity and attention performance are monitored using EEG and specific tests.See study design

What are the potential side effects?

Mecamylamine may cause side effects like dizziness, nausea, dry mouth, constipation, blurred vision or confusion. These symptoms result from its action on the nervous system but vary among individuals.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 55 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ after administration of second drug challenge, approximately 72 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~after administration of second drug challenge, approximately 72 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and after administration of second drug challenge, approximately 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of participants who complete EEG

Proportion of participants who complete study visits with drug challenge

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Anticholinergic ChallengeExperimental Treatment1 Intervention

All participants will receive oral mecamylamine or IV scopolamine for 1 day

Group II: Placebo ChallengePlacebo Group1 Intervention

All participants will receive oral placebo for 1 day

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Vanderbilt University Medical CenterLead Sponsor

857 Previous Clinical Trials

672,117 Total Patients Enrolled

Paul Newhouse, MDStudy DirectorVanderbilt University Medical Center

4 Previous Clinical Trials

669 Total Patients Enrolled

Media Library

Mecamylamine Challenge Clinical Trial Eligibility Overview. Trial Name: NCT04756232 — Phase < 1

Mild Cognitive Impairment Research Study Groups: Anticholinergic Challenge, Placebo Challenge

Mild Cognitive Impairment Clinical Trial 2023: Mecamylamine Challenge Highlights & Side Effects. Trial Name: NCT04756232 — Phase < 1

Mecamylamine Challenge 2023 Treatment Timeline for Medical Study. Trial Name: NCT04756232 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment actively enrolling participants?

"Clinicaltrials.gov documents reveal that this research experiment, which was first advertised on April 21st 2022, is currently enrolling participants. The details of the trial were most recently updated on June 6th 2022."

Answered by AI

How many people is the research team recruiting for this experiment?

"Affirmative, the information on clinicaltrials.gov reveals that this medical investigation is in search of volunteers. This study was initially listed on April 21st 2022 and has recently been modified on June 6th 2022. Twenty individuals are required to be enrolled at single site for successful completion of this trial."

Answered by AI

Have any prior research projects explored the effects of Mecamylamine Challenge?

"Currently, two active medical studies are underway to research Mecamylamine Challenge. These trials are at the Phase 0 level and have locations in both Nashville and Tennessee."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Cholinergic Mechanisms of Attention in Aging

Kimberly Albert 2022. "Cholinergic Mechanisms of Attention in Aging". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04756232.

All > Mci